Has Doris Quon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,020,758 in general payments to Doris Quon, MD across 1,606 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Doris Quon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Doris Quon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Doris Quon, MD

Hematology · Los Angeles, CANPI 1578589271

Payments from drug & device makers

$2,020,758in general payments, 2019–2025

Across 1,606 payments — averaging $1258.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biomarin Pharmaceutical Inc.$397K
Sanofi$330K
Novo Nordisk$302K
CSL Behring$224K
HEMA Biologics, LLC$214K
Genentech USA, Inc.$95K
plus $459K from 54 others

$30,340in research payments, 2019–2025

Across 26 payments — averaging $1166.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$14K
Sanofi$10K
Bioverativ Therapeutics Inc.$5K
Pfizer$940

What the payments were for

Consulting fees$354,66924%
Speaking & faculty fees$910,18162%
Travel & lodging$168,00411%
Food & beverage$28,6752%
Education$1060%
Gifts$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biomarin Pharmaceutical Inc.	135	$397,055
Sanofi	228	$329,623
Novo Nordisk	185	$301,606
CSL Behring	186	$224,087
HEMA Biologics, LLC	232	$214,286
Genentech USA, Inc.	85	$94,552
Bayer	95	$86,034
Shire North American Group Inc	78	$84,218
Genentech, Inc.	12	$80,934
Bioverativ Therapeutics Inc.	31	$55,282
Sanofi US Services Inc.	10	$48,765
Takeda Pharmaceuticals U.S.A., Inc.	56	$45,070
Pfizer	43	$44,727
Octapharma USA, Inc.	16	$5,982
F. Hoffmann-la Roche AG	1	$2,420
Novo Nordisk Health Care AG	1	$595
E.r. Squibb & Sons, L.L.C.	14	$492
Spark Therapeutics, Inc.	9	$445
Novartis	20	$391
Daiichi Sankyo Inc.	14	$359
Amgen	15	$354
Seagen Inc.	12	$283
Bio Products Laboratory USA, Inc.	6	$231
Incyte Corporation	5	$200
AstraZeneca(2 entities)	9	$190
Taiho Oncology, Inc.	7	$142
Bristol Myers Squibb	5	$122
Merck	5	$120
Epizyme, Inc.	2	$116
Kedrion Biopharma, Inc.	3	$114
Tersera Therapeutics LLC	4	$114
Beigene USA, Inc.	4	$96
AbbVie	4	$94
Karyopharm Therapeutics Inc.	3	$91
Kyowa Kirin, Inc.	4	$91
Johnson & Johnson	4	$91
Genmab U.S., Inc.	3	$77
Array Biopharma Inc	3	$73
Rigel Pharmaceuticals, Inc.	1	$64
Astellas Pharma US Inc	3	$64
Lilly USA, LLC	3	$64
Fresenius Kabi USA, LLC	3	$61
Eisai Inc.	3	$60
GSK	3	$58
Gilead	3	$53
Aadi Bioscience, Inc.	3	$48
Sobi, Inc	2	$48
Coherus Oncology, Inc.	2	$47
Sanofi-aventis U.S. LLC	1	$45
Dova Pharmaceuticals	2	$44
Spectrum Pharmaceuticals Inc.	1	$43
Teva Pharmaceuticals USA, Inc.	2	$42
Tolmar Pharmaceuticals, Inc.	2	$41
Deciphera Pharmaceuticals Inc.	2	$40
Dendreon Pharmaceuticals LLC	1	$34
Jazz Pharmaceuticals Inc.	1	$32
Agios Pharmaceuticals, Inc.	1	$27
CTI Biopharma Corp.	1	$26
Stemline Therapeutics Inc.	1	$25
Mylan Institutional Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ALTUVIIIO$196,259
HEMGENIX$193,889
SevenFact$178,353
HEMLIBRA$95,101
ADVATE$64,557
REBINYN$56,581
ELOCTATE$56,180
Esperoct$49,286
ALPROLIX$39,904
QFITLIA$25,329
Jivi$21,610
Alhemo$19,933
NovoSeven RT$17,167
NovoSeven$15,144
ADYNOVATE$11,800
Idelvion$7,156
HYMPAVZI$7,131
Novoeight$6,573
NUWIQ$5,702
BENEFIX$5,000

How this compares

$2,020,758 in reported general payments places this provider in the 75th percentile of 178 hematology providers in California.

See all hematology providers in California →

Medicare billing

Part B allowed, 2024

$15,074

Medicare patients

Services billed

139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Los Angeles

Ilene WeitzLos Angeles$5.2M
Caroline PiatekLos Angeles$1.4M
Tait ShanafeltStanford$441.4M
Alex HerreraDuarte$50.9M
Hope RugoSan Francisco$23.8M
Tycel PhillipsDuarte$21.6M
Lihua BuddeDuarte$21.5M
Tanya SiddiqiDuarte$18.8M
Amrita KrishnanDuarte$14M
Anthony SteinDuarte$12.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →